ATE424825T1 - Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten - Google Patents
Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefizitenInfo
- Publication number
- ATE424825T1 ATE424825T1 AT02756536T AT02756536T ATE424825T1 AT E424825 T1 ATE424825 T1 AT E424825T1 AT 02756536 T AT02756536 T AT 02756536T AT 02756536 T AT02756536 T AT 02756536T AT E424825 T1 ATE424825 T1 AT E424825T1
- Authority
- AT
- Austria
- Prior art keywords
- attention deficit
- treatment
- hyperactivity disorders
- hyperactivity
- disorders
- Prior art date
Links
- 208000013403 hyperactivity Diseases 0.000 title abstract 2
- 230000006735 deficit Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 2
- WVLHGCRWEHCIOT-UHFFFAOYSA-N eltoprazine Chemical compound C1CNCCN1C1=CC=CC2=C1OCCO2 WVLHGCRWEHCIOT-UHFFFAOYSA-N 0.000 abstract 1
- 229950006047 eltoprazine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30682501P | 2001-07-20 | 2001-07-20 | |
US38293102P | 2002-05-23 | 2002-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE424825T1 true ATE424825T1 (de) | 2009-03-15 |
Family
ID=26975388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02756536T ATE424825T1 (de) | 2001-07-20 | 2002-07-19 | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
Country Status (11)
Country | Link |
---|---|
US (5) | US7504395B2 (de) |
EP (2) | EP2036547A3 (de) |
JP (1) | JP5080716B2 (de) |
AT (1) | ATE424825T1 (de) |
AU (2) | AU2002322539B2 (de) |
CA (1) | CA2453837C (de) |
DE (1) | DE60231507D1 (de) |
DK (1) | DK1408976T5 (de) |
ES (1) | ES2323451T7 (de) |
HK (1) | HK1065478A1 (de) |
WO (1) | WO2003007956A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
ATE424825T1 (de) * | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
US8751031B2 (en) * | 2004-02-06 | 2014-06-10 | Zircore, Llc | System and method for mass custom manufacturing of dental crowns and crown components |
CA2614282A1 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
CA2725356C (en) * | 2008-05-30 | 2018-10-16 | Psychogenics, Inc. | Use of eltoprazine for improving symptoms of cognitive impairment associated with non-adhd neurological and mental disorders |
US20120077818A1 (en) * | 2009-05-13 | 2012-03-29 | Sunovion Pharmaceuticals Inc. | Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof |
CN102481291B (zh) * | 2009-06-25 | 2015-10-21 | 阿尔考布拉有限公司 | 用于治疗、减轻症状、缓解、改善和预防认知疾病、障碍或病症的方法 |
WO2011000564A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of drug addiction |
EP2448579A1 (de) | 2009-06-30 | 2012-05-09 | Merz Pharma GmbH & Co. KGaA | Eltoprazin zur behandlung von gewichtsstörungen |
EP2448580A1 (de) | 2009-06-30 | 2012-05-09 | Merz Pharma GmbH & Co. KGaA | Eltoprazin zur behandlung von angstzuständen |
WO2011000562A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of certain movement disorders |
US8770980B2 (en) * | 2009-09-29 | 2014-07-08 | Advanced Training System Llc | System, method and apparatus for adaptive driver training |
WO2014180556A1 (en) * | 2013-05-06 | 2014-11-13 | Merz Pharma Gmbh & Co. Kgaa | Arylpiperazines |
JP7406285B1 (ja) | 2023-03-09 | 2023-12-27 | 国立大学法人島根大学 | ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンudp-グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物 |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4039653A (en) * | 1974-01-23 | 1977-08-02 | Defoney, Brenman, Mayes & Baron | Long-acting articles for oral delivery and process |
CH653021A5 (fr) | 1981-04-24 | 1985-12-13 | Delalande Sa | Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant. |
FR2524312B1 (fr) * | 1982-04-01 | 1985-10-04 | Tech Cuir Centre | Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif |
ZA848005B (en) | 1983-10-17 | 1985-05-29 | Duphar Int Res | Blood-pressure lowering piperazine derivatives |
EP0190472B1 (de) | 1984-12-21 | 1989-07-12 | Duphar International Research B.V | Arzneimittel mit antipsychotischer Wirkung |
EP0189612B1 (de) | 1984-12-21 | 1992-11-04 | Duphar International Research B.V | Arzneimittel mit psychotroper Wirkung |
GB8521494D0 (en) * | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
US4797286A (en) * | 1985-11-12 | 1989-01-10 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
ZA871335B (en) | 1986-02-27 | 1987-09-30 | Duphar Int Res | New aryl-substituted(n-piperidinyl)methyl-and(n-piperazinyl)-methylazoles having antipsychotic properties |
GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
MX173362B (es) | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
US4889852A (en) | 1987-09-11 | 1989-12-26 | Duphar International Research B.V. | Anxiolytically active piperazine derivatives |
US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
NZ231631A (en) | 1988-12-08 | 1992-07-28 | Duphar Int Res | Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions |
GB8830312D0 (en) | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
SE8904361D0 (sv) | 1989-12-22 | 1989-12-22 | Astra Ab | New chroman and thiochroman derivatives |
FR2670491B1 (fr) | 1990-12-14 | 1993-02-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
IL101722A (en) | 1991-05-02 | 1996-05-14 | Wyeth John & Brother Ltd | History of piperazine, their preparation and pharmaceutical preparations containing them |
IT1251144B (it) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
GB9125900D0 (en) | 1991-12-05 | 1992-02-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
EP0556889A1 (de) | 1992-02-18 | 1993-08-25 | Duphar International Research B.V | Verfahren zur Herstellung von Aryl(Homo)Piperazine |
FR2692264B1 (fr) | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
DK148392D0 (da) | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
ES2134241T3 (es) | 1992-12-21 | 1999-10-01 | Duphar Int Res | Procedimiento enzimatico para la preparacion estereoselectiva de un enantiomero de alcohol hetero-biciclico. |
RU2118322C1 (ru) | 1993-07-05 | 1998-08-27 | Дюфар Интернэшнл Рисерч Б.В. | 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли |
KR0177894B1 (ko) * | 1993-07-28 | 1999-03-20 | 아만 히데아키 | 항우울제 |
EP0724580A1 (de) | 1993-10-19 | 1996-08-07 | Smithkline Beecham Plc | Benzamilid-derivate als 5ht-1d-rezeptor antagonisten |
EP0650964A1 (de) | 1993-11-02 | 1995-05-03 | Duphar International Research B.V | 1- 2H-1-Benzopyran-2-on-8-yl -Piperazin Derivate |
IL112764A0 (en) | 1994-03-18 | 1995-05-26 | Ferrer Int | New chromene derivatives |
WO1996000720A1 (en) | 1994-06-29 | 1996-01-11 | Pfizer Inc. | Aryl and heteroaryl alkoxynaphthalene derivatives |
FR2725623A1 (fr) * | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
EP0710481A1 (de) | 1994-11-02 | 1996-05-08 | Duphar International Research B.V | Verwendung von Flesinoxan zur Wahrnehmungssteigerung |
WO1996017831A1 (de) | 1994-12-07 | 1996-06-13 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Uracilderivate |
US5741789A (en) | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
WO1997003067A1 (en) | 1995-07-13 | 1997-01-30 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
GB9514901D0 (en) | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
SE9601110D0 (sv) | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
IL126187A0 (en) | 1996-03-29 | 1999-05-09 | Duphar Int Res | Piperazine and piperidine compounds |
US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
DE69722020T2 (de) | 1996-10-15 | 2004-01-22 | Wyeth | Azaheterocyclylmethyl-derivate von 2,3,8,9-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-on |
FR2760014B1 (fr) | 1997-02-27 | 1999-04-09 | Adir | Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
DE19730989A1 (de) * | 1997-07-18 | 1999-01-21 | Merck Patent Gmbh | Piperazin-Derivate |
DE69819173T2 (de) | 1997-07-25 | 2004-04-15 | H. Lundbeck A/S | Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung |
US5942244A (en) * | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
DE69819266T2 (de) | 1997-09-02 | 2004-07-29 | Duphar International Research B.V. | Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten |
SE9703376D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
SE9703378D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
SE9703374D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
FR2769312B1 (fr) | 1997-10-03 | 1999-12-03 | Adir | Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
IL127497A (en) | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
US6310066B1 (en) | 1998-04-29 | 2001-10-30 | American Home Products Corp. | Antipsychotic indolyl derivatives |
US6387904B2 (en) | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
PT985414E (pt) | 1998-05-26 | 2004-01-30 | Pfizer Prod Inc | Metodo de tratamento de glaucoma e retinopatia isquemica |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6376494B1 (en) | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6242448B1 (en) | 1998-12-17 | 2001-06-05 | American Home Products Corporation | Trisubstituted-oxazole derivatives as serotonin ligands |
US6313126B1 (en) | 1999-01-07 | 2001-11-06 | American Home Products Corp | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
US6306859B1 (en) | 1999-03-02 | 2001-10-23 | American Home Products Corporation | N-substituted imide derivatives with serotonergic activity |
ES2162731B1 (es) | 1999-06-04 | 2003-02-16 | Faes Fabrica Espanola De Produ | Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas. |
US6638936B1 (en) | 1999-07-29 | 2003-10-28 | Eli Lilly And Company | Benzofurylpiperazine serotonin agonists |
EP1204654B1 (de) * | 1999-07-29 | 2003-07-23 | Eli Lilly And Company | Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten |
AR027133A1 (es) | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de heteroarilo, su preparacion y uso. |
NZ522116A (en) | 2000-05-12 | 2004-04-30 | Solvay Pharmaceuticals B | Piperazine and piperidine compounds that have partial agonism towards dopamine D2-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors |
EP1284731A1 (de) | 2000-05-12 | 2003-02-26 | Solvay Pharmaceuticals B.V. | Verwendung von verbindungen mit kombinierter d2, 5-ht1a und alpha adrenoceptor agonistischer wirkung zur behandlung von zns-erkrankungen |
US20020016334A1 (en) | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
DE10041574A1 (de) | 2000-08-24 | 2002-03-07 | Merck Patent Gmbh | Chromenonderivate |
DE10043659A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazinderivate |
US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
CA2426031C (en) * | 2000-11-02 | 2011-10-04 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
US6469007B2 (en) | 2000-11-28 | 2002-10-22 | Wyeth | Serotonergic agents |
ES2188344B1 (es) | 2000-11-29 | 2004-09-16 | Laboratorios Vita, S.A. | Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos. |
AR032711A1 (es) | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene |
ES2252471T3 (es) | 2001-06-29 | 2006-05-16 | H. Lundbeck A/S | Nuevos derivados de heteroarilo, su preparacion y uso. |
ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
HU227237B1 (en) | 2001-09-27 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them |
ITMI20012060A1 (it) | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
EP1336406A1 (de) | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Partieller Dopamin-D2 Rezeptoragonist plus Substanzen mit Serotonin- und/oder Noradrenalin inhibitorischer Aktivität |
RU2315762C2 (ru) | 2002-03-12 | 2008-01-27 | Уайт | Способ синтеза хиральных n-арилпиперазинов |
SI1483243T1 (sl) | 2002-03-12 | 2007-08-31 | Wyeth Corp | Priprava n1- (2'-piridil)-1,2-propandiamin sulfamske kisline in uporaba spojine za sintezo bioloĺ ko aktivnih piperazinov |
IL163828A0 (en) | 2002-03-12 | 2005-12-18 | Wyeth Corp | Process for making chiral 1,4-disubstituted piperazines |
PL211057B1 (pl) | 2002-05-13 | 2012-04-30 | Hoffmann La Roche | Pochodne benzoksazyny, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie pochodnych benzoksazyny |
US20040072839A1 (en) | 2002-06-14 | 2004-04-15 | Amedeo Leonardi | 1-Phenylalkylpiperazines |
US20040002500A1 (en) | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
US7067518B2 (en) | 2002-09-05 | 2006-06-27 | Wyeth | Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents |
US7153849B2 (en) | 2002-09-12 | 2006-12-26 | Wyeth | Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans |
CA2505334A1 (en) | 2002-11-08 | 2004-05-21 | F. Hoffmann-La Roche Ag | Substituted benzoxazinones and uses thereof |
US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
WO2004069339A1 (en) | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
ATE381334T1 (de) | 2003-03-03 | 2008-01-15 | Hoffmann La Roche | 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren |
WO2004100954A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Treatment of psychotic and depressive disorders |
MXPA05012392A (es) | 2003-05-16 | 2006-02-02 | Pfizer Prod Inc | Tratamientos de ansiedad con ziprasidona. |
WO2004100957A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Treatment of bipolar disorders and associated symptoms |
CA2525323A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Method for enhancing cognition using ziprasidone |
US20050065158A1 (en) | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
US7435738B2 (en) | 2003-08-18 | 2008-10-14 | Solvay Pharmaceuticals, Inc. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
BRPI0416873A (pt) | 2003-12-09 | 2007-02-27 | Hoffmann La Roche | derivados de benzoxazina e usos dos mesmos |
-
2002
- 2002-07-19 AT AT02756536T patent/ATE424825T1/de not_active IP Right Cessation
- 2002-07-19 DE DE60231507T patent/DE60231507D1/de not_active Expired - Lifetime
- 2002-07-19 DK DK02756536.5T patent/DK1408976T5/da active
- 2002-07-19 EP EP08173141A patent/EP2036547A3/de not_active Withdrawn
- 2002-07-19 CA CA2453837A patent/CA2453837C/en not_active Expired - Fee Related
- 2002-07-19 JP JP2003513563A patent/JP5080716B2/ja not_active Expired - Fee Related
- 2002-07-19 AU AU2002322539A patent/AU2002322539B2/en not_active Ceased
- 2002-07-19 US US10/199,634 patent/US7504395B2/en not_active Expired - Fee Related
- 2002-07-19 EP EP02756536A patent/EP1408976B3/de not_active Expired - Lifetime
- 2002-07-19 WO PCT/US2002/023081 patent/WO2003007956A1/en active Application Filing
- 2002-07-19 ES ES02756536T patent/ES2323451T7/es active Active
-
2004
- 2004-10-21 HK HK04108300.4A patent/HK1065478A1/xx not_active IP Right Cessation
-
2005
- 2005-09-02 US US11/219,416 patent/US7557109B2/en not_active Expired - Fee Related
-
2007
- 2007-12-24 AU AU2007254677A patent/AU2007254677B2/en not_active Ceased
-
2008
- 2008-12-24 US US12/344,051 patent/US20090104261A1/en not_active Abandoned
-
2010
- 2010-09-20 US US12/885,822 patent/US20110008425A1/en not_active Abandoned
-
2011
- 2011-08-16 US US13/210,474 patent/US20120070494A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2036547A2 (de) | 2009-03-18 |
EP1408976B3 (de) | 2010-08-25 |
DK1408976T5 (da) | 2011-01-10 |
US20110008425A1 (en) | 2011-01-13 |
HK1065478A1 (en) | 2005-02-25 |
WO2003007956A1 (en) | 2003-01-30 |
US20120070494A1 (en) | 2012-03-22 |
AU2002322539B2 (en) | 2007-09-27 |
CA2453837A1 (en) | 2003-01-30 |
AU2007254677B2 (en) | 2009-11-12 |
DK1408976T3 (da) | 2009-06-29 |
JP5080716B2 (ja) | 2012-11-21 |
CA2453837C (en) | 2011-10-04 |
EP2036547A3 (de) | 2009-12-23 |
US20090104261A1 (en) | 2009-04-23 |
JP2004538282A (ja) | 2004-12-24 |
AU2007254677A1 (en) | 2008-01-24 |
EP1408976A4 (de) | 2007-05-16 |
ES2323451T3 (es) | 2009-07-16 |
EP1408976B1 (de) | 2009-03-11 |
US7504395B2 (en) | 2009-03-17 |
EP1408976A1 (de) | 2004-04-21 |
DE60231507D1 (de) | 2010-07-01 |
US20060004023A1 (en) | 2006-01-05 |
US7557109B2 (en) | 2009-07-07 |
ES2323451T7 (es) | 2011-08-01 |
US20030050308A1 (en) | 2003-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE424825T1 (de) | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten | |
ATE296634T1 (de) | (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
ATE415968T1 (de) | 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen | |
DE60231804D1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen | |
ATE514430T1 (de) | Behandlung des alpha-galactosidase a mangels | |
DE69534130D1 (de) | Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen. | |
ATE427759T1 (de) | Behandlung von fettsucht und verbundenen erkrankungen | |
ATE535236T1 (de) | Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit | |
ATE286028T1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
HK1159514A1 (en) | Ht0712 for the treatment of a cognitive deficit ht0712 | |
DE602005026276D1 (de) | Myricitrin verbindungen zur behandlung von schlafstörungen | |
CY1109238T1 (el) | Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη | |
ATE316787T1 (de) | Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion | |
ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
ATE400564T1 (de) | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen | |
TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
ATE359783T1 (de) | Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems | |
NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
DE602004026597D1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
ATE443262T1 (de) | Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen | |
DE60213234D1 (de) | 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts | |
DE60335610D1 (de) | Neoplasma-spezifische antikörper und deren verwendungen | |
ATE491442T1 (de) | 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
DE60327335D1 (de) | Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |